Albiruni Ryan Abdul Razak

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations

Medicine, Oncology, Pharmacology +17

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2016 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Mrinal M. Gounder, Alona Zer, William D. Tap et al. · Journal of Clinical Oncology · 2016 · 165 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

Yung‐Jue Bang, Toshio Doi, Filippo de Braud et al. · European Journal of Cancer · 2015 · 145 citations

Medicine, Oncology, Pharmacology +7

Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

Fiona A. Miller, Robin Z. Hayeems, Jessica Bytautas et al. · European Journal of Human Genetics · 2013 · 120 citations

Medicine, Genetics, Oncology +17